Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL898825 | 0.82 | POLB (0.47) | KDM4EHTTMAPK1ALDH1A1GAA | |
| SCHEMBL17635838 | 0.80 | KDM4E (0.47) | KDM4EHTTMAPK1AURKARPS6KB1 | |
| SCHEMBL15733283 | 0.79 | AURKA (0.47) | KDM4EHTTMAPK1AURKARPS6KB1 | |
| SCHEMBL2351827 | 0.77 | CHRNB2 (0.41) | — | |
| SCHEMBL2347716 | 0.77 | L3MBTL1 (0.39) | KDM4EHTTALDH1A1GAASLC9A1 | |
| SCHEMBL2344594 | 0.77 | POLB (0.46) | KDM4EHTTMAPK1ALDH1A1GAA | |
| SCHEMBL21834760 | 0.76 | KDM4E (0.44) | KDM4EHTTMAPK1AURKARPS6KB1 | |
| SCHEMBL2231719 | 0.72 | AURKA (0.50) | KDM4EHTTMAPK1AURKARPS6KB1 | |
| SCHEMBL13780205 | 0.72 | KDM4E (0.46) | KDM4EHTTMAPK1ALDH1A1GAA | |
| SCHEMBL15650913 | 0.71 | IKBKB (0.48) | KDM4EHTTALDH1A1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127237-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MEDIBEACON INC. | 2022-04-28 | — | — | US | disclosed |
| US-10617687-B2 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | MEDIBEACON INC. (US) | 2020-04-14 | — | — | US | disclosed |
| US-20170298030-A9 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | Medibeacon, LLC | 2017-10-19 | — | — | US | disclosed |
| US-20160280666-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MEDIBEACON INC (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160280665-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | Medibeacon, LLC | 2016-09-29 | — | — | US | disclosed |
| US-9376399-B2 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | MEDIBEACON LLC (US) | 2016-06-28 | — | — | US | disclosed |
| US-8778309-B2 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | MEDIBEACON LLC (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140039191-A1 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function | Medibeacon, LLC (US) | 2014-02-06 | — | — | US | disclosed |
| EP-1854790-B1 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | MALLINCKRODT INC (US) | 2011-08-31 | — | — | EP | disclosed |
| EP-1836175-B1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MALLINCKRODT INC (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-2135863-A1 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | Mallinckrodt, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2039688-A1 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | Mallinckrodt, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20090010851-A1 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function | MALLINCKRODT INC. (US) | 2009-01-08 | — | — | US | disclosed |
| EP-1854790-A1 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | Mallinckrodt, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1836175-A2 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MALLINCKRODT, INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006071759-A2 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MALLINCKRODT INC. (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127237-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | GLS, XDH, CYP4F12 | KDM4E 2713/4885HTT 3732/4885MAPK1 2878/4885 |
| US-10617687-B2 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | GLS, CYP4F12, XDH | KDM4E 3146/4885HTT 3516/4885MAPK1 3136/4885 |
| US-20160280665-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | GLS, CYP4F12, XDH | KDM4E 3146/4885HTT 3516/4885MAPK1 3136/4885 |
| US-20160280666-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | GLS, CYP4F12, XDH | KDM4E 3146/4885HTT 3516/4885MAPK1 3136/4885 |
| US-20170298030-A9 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | GLS, CYP4F12, XDH | KDM4E 3146/4885HTT 3516/4885MAPK1 3136/4885 |
| US-20090010851-A1 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function | GLS, CYP4F12, XDH | KDM4E 3146/4885HTT 3516/4885MAPK1 3136/4885 |
| US-20140039191-A1 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function | GLS, CYP4F12, XDH | KDM4E 3146/4885HTT 3516/4885MAPK1 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.